FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 348:1537-1545 April 17, 2003 Number 16 Next

Abstract PDF PDA Full Text PowerPoint Slide Set Editorial by Curfman, G. D. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background Intimal hyperplasia and resulting restenosis limit the efficacy of coronary stenting. We studied a coronary stent coated with the antiproliferative agent paclitaxel as a means of preventing restenosis.

Methods We conducted a multicenter, randomized, controlled, triple-blind study to evaluate the ability of a paclitaxel-eluting stent to inhibit restenosis. At three centers, 177 patients with discrete coronary lesions (<15 mm in length, 2.25 to 3.5 mm in diameter) underwent implantation of paclitaxel-eluting stents (low dose, 1.3 µg per square millimeter, or high dose, 3.1 µg per square millimeter) or control stents. Antiplatelet therapies included aspirin with ticlopidine (120 patients), clopidogrel (18 patients), or cilostazol (37 patients). Clinical follow-up was performed at one month and four to six months, and angiographic follow-up at four to six months.

Results Technical success was achieved in 99 percent of the patients (176 of 177). At follow-up, the high-dose group, as compared with the control group, had significantly better results for the degree of stenosis (mean [±SD], 14±21 percent vs. 39±27 percent; P<0.001), late loss of luminal diameter (0.29±0.72 mm vs. 1.04±0.83 mm, P<0.001), and restenosis of more than 50 percent (4 percent vs. 27 percent, P<0.001). Intravascular ultrasound analysis demonstrated a dose-dependent reduction in the volume of intimal hyperplasia (31, 18, and 13 mm³, in the high-dose, low-dose, and control groups, respectively). There was a higher rate of major cardiac events in patients receiving cilostazol than in those receiving ticlopidine or clopidogrel. Among patients receiving ticlopidine or clopidogrel, event-free survival was 98 percent and 100 percent in the high-dose and control groups, respectively, at one month, and 96 percent in both at four to six months.

Conclusions Paclitaxel-eluting stents used with conventional antiplatelet therapy effectively inhibit restenosis and neointimal hyperplasia, with a safety profile similar to that of standard stents.

Paclitaxel inhibits cell processes that are dependent on microtubule turnover, including mitosis, cell proliferation, and cell migration, while the cells remain viable and in a cytostatic state.^{10,11,12,13,14} In vitro tests show cytostatic inhibition of smooth-muscle cells with therapeutic concentrations of paclitaxel. For this reason, paclitaxel was considered for intracoronary delivery to arrest the process responsible for neointimal hyperplasia after angioplasty and stenting.^14,15,16,17

Preclinical testing using a porcine coronary-artery model showed inhibition of neointimal hyperplasia at one month over a range of doses, all with acceptable safety. Although delayed endothelialization was noted on histologic examination, reinforcing the need for antiplatelet therapy, results did not suggest subacute thrombotic complications while patients were receiving ticlopidine. In a subsequent six-month study in which ticlopidine was discontinued one month after stent implantation, there were no late deaths from stent thrombosis. Given this promising evidence of effectiveness and acceptable safety profile, further study was considered to be warranted.

We designed a multicenter, prospective, randomized study to test the hypothesis that stents coated with paclitaxel would inhibit neointimal hyperplasia in patients with coronary artery disease requiring stenting of single new native lesions. Our study, the Asian Paclitaxel-Eluting Stent Clinical Trial (ASPECT), compared the safety and effectiveness of paclitaxel-eluting stents with the safety and effectiveness of uncoated stents of the same type.

Methods

Selection of Patients

Symptomatic patients were included if they were at least 18 years old and volunteered for follow-up. Criteria for exclusion included an ejection fraction of less than 35 percent; coagulopathy; intractable hypersensitivities; the performance of other studies within the previous 30 days; pregnancy; a life expectancy of less than 1 year; myocardial infarction within the previous 72 hours; other revascularization procedures within the previous 1 month; the presence of coronary thrombus; severe calcification; total occlusion; another stenosis of more than 50 percent in the target vessel; a lesion length greater than 15 mm; multiple stents; proximal tortuosity; angulation of more than 45 percent; unprotected left-main coronary lesions; and poor distal runoff. The protocol was approved by the appropriate ethics committees. Participants gave written informed consent, and the study was conducted between January 2000 and March 2001 in accordance with the Declaration of Helsinki.

Study Design

The three-center randomized study compared stents coated with one of two doses of paclitaxel with an uncoated control stent of the same design. The study population was stratified according to stent diameter and was randomized in blocks (in a ratio of 1:1:1). Stents (Cook) of each diameter were ordered in a randomized sequence. After angiography to determine vessel diameter, stents of the appropriate diameter were selected in order of sequence. The patients, investigators, and core-analysis laboratories were all unaware of the random group assignments.

Angioplasty and Stenting Procedure

Standard angioplasty and stent placement were performed with a radial or femoral approach and an over-the-wire technique. Lesions were predilated with a standard balloon equal to or smaller than the diameter of the reference vessel. The stent, premounted on a semicompliant balloon, was chosen to achieve a stent-to-artery ratio of approximately 1.1:1.0. The stent was delivered by low-pressure inflation and dilated if necessary to achieve minimal residual stenosis (<10 percent). In the event of a distal or proximal dissection, a second uncoated stent of either the study type or another type was placed.

The stent used in the study was a 15-mm-long Supra-G stent (Cook) in diameters of 2.5, 3.0, and 3.5 mm. The polished stainless-steel, laser-cut cannula design had a large surface area (42 to 47 mm², depending on the diameter). A proprietary process was used to bond paclitaxel, at a dose density of 3.1 µg per square millimeter or 1.3 µg per square millimeter, to the abluminal surface of the stents without the use of a polymer. The total amount of paclitaxel per stent was 130 to 146 µg in the group that received stents with the dose of 3.1 µg per square millimeter and 54 to 60 µg in the group that received stents with the dose of 1.3 µg per square millimeter, depending on the diameter of the stent.

The protocol recommended treatment with soluble aspirin and clopidogrel or ticlopidine before the procedure. Heparin was administered during the procedure according to standard practice. After the procedure, in addition to aspirin, ticlopidine or clopidogrel was recommended for one month at two centers and for six months at the third center. Cilostazol^18,19,20 was administered in lieu of ticlopidine or clopidogrel in 37 patients, as was standard practice for patients with stents at two centers.

Study End Points

Clinical follow-up was performed at one month and again at four to six months; angiographic follow-up was performed at four to six months. The primary end point was the percentage stenosis at angiographic follow-up, as determined by independent quantitative angiographic analysis. Secondary angiographic end points included late loss, the rate of restenosis (defined as stenosis of more than 50 percent of the luminal diameter), and the in-stent minimal luminal diameter. Secondary clinical end points included the incidence of death, acute and subacute thrombosis, the need for coronary bypass surgery or intervention to treat clinical ischemia due to restenosis of the target lesion, and myocardial infarction (Q-wave or non–Q-wave) due to restenosis of the target lesion. Q-wave myocardial infarction was defined by the postprocedural presence of new Q waves greater than 0.04 second in two contiguous leads. Non–Q-wave myocardial infarction was defined as investigator-identified, clinically significant myocardial infarction involving peak creatine kinase values greater than twice the upper limit of normal and a creatine kinase MB fraction greater than twice the upper limit of normal.

Clinical events were adjudicated by an independent clinical-events committee (Harvard Clinical Research Institute, Boston). Safety data were reviewed by an independent data safety monitoring board (Willis Tacker, M.D., Ph.D., Seattle, Chairman). Data were collected with standardized case-report forms that were completed by the research coordinator at each site. Representatives from the data-coordinating center monitored the sites.

Angiographic Analysis

Procedural and follow-up angiograms were submitted to an independent angiographic core laboratory (Methodist Hospital, Houston). Quantitative angiographic analysis was performed (CAAS II, Pie Medical) for standard qualitative and quantitative characteristics such as luminal dimensions, including proximal and distal references, and the minimal luminal diameter before and after the procedure and at follow-up. Angiograms were evaluated qualitatively for morphologic features of the lesion, flow grade, dissection grade, and branches larger than 2 mm.

Intravascular-Ultrasound Substudy

Eighty-one patients at one center underwent an intravascular-ultrasound substudy designed to provide more detailed information about the mechanism of inhibition of restenosis. Automatic pullback images were obtained after stent placement and at four to six months of follow-up. Imaging extended up to 5 mm distally and 5 mm proximally in most patients. The postprocedural and follow-up images were submitted to an independent, blinded core laboratory (Cardiovascular Research Institute, Washington, D.C.) for analysis. Luminal, stent, vessel, and neointimal volumes were calculated from automated pullback images with use of Simpson's rule with 1-mm intervals.

Statistical Analysis

The study was designed by the academic investigators and commercial sponsor and had sufficient power to detect a 15 percent difference in the angiographically determined percentage of stenosis at six months, for an alpha level of 0.05 and a beta of 0.20; it was calculated that a minimum of 50 patients was required per treatment group, assuming a 90 percent follow-up.

Continuous variables are reported as means ±SD. Effects across all three groups were analyzed by analysis of variance, and pairwise comparisons were performed with an unpaired t-test. Dichotomous variables are reported as percentages with 95 percent confidence intervals; comparisons were performed with a Pearson's chi-square or Fisher's exact test. Analysis was performed on an intention-to-treat basis including all patients for whom data were available from the follow-up analysis. All data were available to the investigators, and the data analysis was performed independently of the sponsor.

Results

Demographic and Clinical Characteristics

Between January 2000 and March 2001, 177 patients were enrolled: 60 in the high-dose group, 58 in the low-dose group, and 59 in the control group. Stent implantation was successful in 176 patients (99.4 percent); 1 patient did not receive a stent because of tortuosity. Analysis of demographic and base-line characteristics showed no significant differences among groups (Table 1). The patients' characteristics were typical of those of patients with noncomplex lesions. Multivessel disease was present in 40 percent of the patients. The lesions treated are described qualitatively and quantitatively as assessed by the independent core laboratory in Table 2; no significant differences existed among the groups.

View this table: [in this window] [in a new window]   Table 1. Base-Line Demographic Characteristics of the Patients.

 

View this table: [in this window] [in a new window]   Table 2. Characteristics of the Lesions in Patients Who Received Stents.

 
At discharge, all but one patient received aspirin, and no patient received warfarin. In addition to aspirin, 120 received ticlopidine after the procedure and at discharge (26 for one month and 94 for six months); of these, 1 also received postprocedural abciximab, and 3 also received postprocedural standard heparin. Eighteen received clopidogrel for one month, without postprocedural abciximab or heparin. Thirty-seven received cilostazol (29 for one month and 8 for six months); 1 also had abciximab after the procedure, and 3 had standard heparin after the procedure. One patient received aspirin and ticlopidine after the procedure but did not take aspirin or ticlopidine after discharge, because of clinically significant urethral bleeding.

Angiographic Outcomes

Angiographic measures are shown in Table 3; angiographic follow-up was obtained for 155 patients (88 percent), at a mean of 174±44 days (range, 85 to 412, including early symptomatic interventions). The results demonstrated a dose-dependent reduction in the primary end point, the percentage of stenosis (39±27 percent in the control group, vs. 23±25 percent in the low-dose group and 14±21 percent in the high-dose group; P<0.001).

View this table: [in this window] [in a new window]   Table 3. Angiographic Measures, According to the Dose of Paclitaxel.

 
Late loss of luminal diameter involved a dose-dependent reduction as well (1.04±0.83 mm in the controls, 0.57±0.71 mm in the low-dose group, and 0.29±0.72 mm in the high-dose group; P<0.001). In the calculation of the late-loss index as the slope of the regression line on a graph of late loss versus acute gain, only the control group yielded a slope. In the paclitaxel groups, the correlation coefficient was near zero, indicating no relation between late loss and immediate gain (the luminal diameter immediately after the procedure minus the luminal diameter before the procedure). In lieu of a late-loss index we calculated the late loss divided by the immediate gain for each patient; this ratio was reduced from 0.46±0.37 in the control group to 0.26±0.34 and 0.13±0.33 in the low-dose and high-dose groups, respectively (P<0.001).

The rate of restenosis, defined as stenosis of more than 50 percent, was 27 percent in the control group, 12 percent in the low-dose group, and 4 percent in the high-dose group (P<0.001). These reductions were associated with a dose-dependent improvement in the minimal luminal diameter (1.79±0.86 mm in the controls, vs. 2.28±0.83 mm in the low-dose group and 2.53±0.72 mm in the high-dose group; P<0.001).

Cumulative distribution curves demonstrated a dose-dependent reduction in the degree of stenosis, as shown in Figure 1 for the high-dose group as compared with the control group. Distributions were similar at base line and immediately after stent placement. At follow-up, the distribution in the high-dose group was similar to the distribution immediately after stenting.

View larger version (9K): [in this window] [in a new window]   Figure 1. Cumulative Distribution of the Percentage of Stenosis in the High-Dose and Control Groups. The distributions were similar at base line and immediately after stent placement. At six months, the distribution in the high-dose group remained similar to the distribution immediately after stenting.

 
Intravascular Ultrasound

Intravascular-ultrasound analysis of 81 patients showed a dose-dependent reduction in the volume of neointimal hyperplasia at follow-up (31±22 mm³ in the controls, 18±15 mm³ in the low-dose group, and 13±14 mm³ in the high-dose group; P<0.001). There were no significant differences in any volumes after the procedure, and no significant differences in stent or vessel volume at follow-up.

Safety at One and Six Months

Clinical follow-up was obtained for all patients who received stents at one month and four to six months (135±30 days; range, 57 to 201, including early symptomatic interventions). Major adverse cardiac events are shown in Table 4. Events were classified according to antiplatelet therapy because an adverse effect of cilostazol was observed. Of 138 patients receiving ticlopidine or clopidogrel, the only event reported at one month was a non–Q-wave myocardial infarction due to closure of a side branch evident during stent placement, which was dilated. In 37 patients receiving cilostazol, there were 1 death and 4 subacute thromboses treated with repeated angioplasty within one month. Potential contributing factors included a stent shorter than the lesion, leaving a dissection uncovered, in one case, and a thrombus that was untreated after stenting in another. In each of the three groups, two patients underwent target-lesion revascularization for restenosis within six months. There were no additional events after one month, even for the 73 patients whose ticlopidine, clopidogrel, or cilostazol therapy was discontinued after only one month.

View this table: [in this window] [in a new window]   Table 4. Safety Data at One and Six Months According to Antiplatelet Therapy and Dose of Paclitaxel.

 
Discussion

This study clearly shows that a paclitaxel-coated coronary stent can significantly reduce restenosis in the six months after intervention, thereby addressing a major problem that has plagued angioplasty since its inception and has not been adequately addressed by the introduction of stents. The dose of 3.1 µg per square millimeter was the more effective of the two doses tested and had safety similar to that of other doses within the follow-up period studied, when used with conventional antiplatelet therapy.

The intravascular-ultrasound substudy showed that the reduction in the percentage of stenosis and in late loss and the increase in the minimal luminal diameter were directly due to a reduction in the proliferation of neointimal tissue. They were not associated with a high degree of positive remodeling.

The concept that a bigger stent is better has been predicated on the late-loss index, indicating that approximately half the immediate gain is lost within six months.²¹ Although other therapies such as brachytherapy^22,23 have reduced the late-loss index, in this study we found a near-zero correlation coefficient for paclitaxel-eluting stents. This suggests the bigger-is-better concept may not apply to drug-eluting stents.

The major adverse cardiac events within one month suggest that the paclitaxel-eluting stent is safe at both low and high dose densities if used with conventional thianopyridine antiplatelet therapy. The single event was due to closure of an involved side branch evident at the time of the procedure and therefore appeared to be unrelated to the coating. The incidence of subacute thrombotic events in patients who received cilostazol instead of ticlopidine or clopidogrel suggests that antiplatelet agents may be more important for drug-eluting stents than for uncoated stents and that cilostazol is an inadequate substitute for thianopyridines with paclitaxel-eluting stents.

The absence of additional deaths, myocardial infarctions, or emergency bypass surgeries between one and six months after the procedure suggests that the paclitaxel-eluting stent is reasonably safe during this period at the dose densities studied. The number of additional target-lesion revascularizations for restenosis was similar among treatment groups, despite the significant difference in all angiographic measures of restenosis. This apparent discrepancy was due to the pattern of clinical practice in the participating centers, in which angiographic restenosis is not treated with intervention unless the patient's symptoms are untreatable with medication. Clinical experience at these and other centers suggests that late regression of the stenosis may occur without intervention.^24,25,26,27 In addition, the predominantly simple lesions treated in the study may also contribute to the lack of difference in the rates of revascularization. However, conclusions regarding clinical effect are tentative in this study, whose size was based on an angiographic end point. Nevertheless, given the practice pattern, duration of follow-up, simplicity of lesions, and sample size, the angiographic benefit was not reflected in a beneficial difference in revascularization rates.

The absence of late events also speaks to the issue of extended antiplatelet therapy. Although preclinical studies suggested a small delay in reendothelialization,²⁸ in this clinical study, discontinuation of ticlopidine at one month was not associated with late thrombosis-related events between one and six months. Although the sample size was not sufficient to rule out the need for the extended therapy, there were no deaths, myocardial infarctions, or emergency surgeries between one and six months in the subgroup of 73 patients who received only aspirin after the first month. However, early events among the patients treated with cilostazol suggest that specific, effective antiplatelet therapy is required with antiproliferative-eluting stents.

The results of this study of paclitaxel are similar to those of the Randomized Study with the Sirolimus-Coated Bx Velocity Balloon-Expandable Stent in the Treatment of Patients with de Novo Native Coronary Artery Lesions (RAVEL) of sirolimus.⁷ Both demonstrate the potential of antiproliferative agents to reduce restenosis by inhibiting neointimal hyperplasia.

The study did not have sufficient power to identify infrequent risks, to define fully the need for extended antiplatelet therapy, to explain the observed effect of cilostazol fully, or to assess effectiveness in more complex lesions. The six-month follow-up period leaves unanswered the question of the duration of the benefits seen at six months and the possible long-term adverse effects of drug-eluting stents, whether the drug eluted is paclitaxel or another agent. Larger studies are needed to evaluate more adequately the clinical effect of the use of coated stents for the elimination of restenosis.

From these data, we conclude that paclitaxel-eluting coronary stents significantly improved the angiographic outcome six months after percutaneous transluminal coronary intervention by reducing neointimal hyperplasia after stent placement, resulting in increased vessel diameter, reduced stenosis, and reduced binary restenosis at follow-up. Paclitaxel had a safety profile similar to that of the control stent when used with conventional antiplatelet therapy. The use of cilostazol appeared to be associated with subacute closure in a few patients. Of the dose densities tested, 3.1 µg per square millimeter of abluminal stent surface was the more effective.

Supported by a grant from Cook.

Dr. Weissman reports having received a research grant from Medstar Research Institute, and Dr. Mintz reports having received lecture fees from Boston Scientific.

We are indebted to Dr. Jae-Joong Kim, Dr. Nam Sik Chung, Dr. Seong Yun Cho, and Dr. Yan Wang for their participation in this clinical trial; to Dong Soon Shin, Kyung Hea Park, and Young-Rok Han for research coordination; to Anthony O. Ragheb, Ph.D., for preclinical studies; and to Neal E. Fearnot, Ph.D., and William D. Voorhees, Ph.D., for trial direction and data analysis.

Source Information

From the Asan Medical Center (S.-J.P., S.-W.P., M.-K.H., C.W.L.) and Yonsei Medical Center (W.H.S., D.C., Y.J.) — both in Seoul, South Korea; the University of Hong Kong, Hong Kong, China (D.S.H., R.L.); the Cardiovascular Angiography Analysis Laboratory, Houston (A.E.R.); the Cardiovascular Research Institute, Washington Hospital Center, Washington, D.C. (N.J.W.); and the Cardiovascular Research Foundation, New York (G.S.M.).

Address reprint requests to Dr. Seung-Jung Park at the Asan Medical Center, Division of Cardiology, 388-1 Poongnap-dong, Songpa-ku, Seoul 138-736, South Korea, or at sjpark{at}amc.seoul.kr.

References

1. Lowe HC, Oesterle SN, Khachigian LM. Coronary in-stent restenosis: current status and future strategies. J Am Coll Cardiol 2002;39:183-193. [Free Full Text]
2. Hoffmann R, Mintz GS, Dussaillant GR, et al. Patterns and mechanisms of in-stent restenosis: a serial intravascular ultrasound study. Circulation 1996;94:1247-1254. [Free Full Text]
3. Hanke H, Kamenz J, Hassenstein S, et al. Prolonged proliferative response of smooth muscle cells after experimental intravascular stenting. Eur Heart J 1995;16:785-793. [Free Full Text]
4. Moreno PR, Palacios IF, Leon MN, Rhodes J, Fuster V, Fallon JT. Histopathologic comparison of human coronary in-stent and post-balloon angioplasty restenotic tissue. Am J Cardiol 1999;84:462-466. [CrossRef][Web of Science][Medline]
5. Weissman NJ, Wilensky RL, Tanguay JF, et al. Extent and distribution of in-stent intimal hyperplasia and edge effect in a non-radiation stent population. Am J Cardiol 2001;88:248-252. [CrossRef][Web of Science][Medline]
6. de Feyter PJ, Vos J, Rensing BJ. Anti-restenosis trials. Curr Interv Cardiol Rep 2000;2:326-331. [Medline]
7. Morice M-C, Serruys PW, Sousa JE, et al. A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med 2002;346:1773-1780. [Free Full Text]
8. Sousa JE, Costa MA, Abizaid AC, et al. Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up. Circulation 2001;104:2007-2011. [Free Full Text]
9. Rensing BJ, Vos J, Smits PC, et al. Coronary restenosis elimination with a sirolimus eluting stent: first European human experience with 6-month angiographic and intravascular ultrasound follow-up. Eur Heart J 2001;22:2125-2130. [Free Full Text]
10. Shiff PB, Fant J, Horwitz SB. Promotion of microtubule assembly in vitro by Taxol. Nature 1979;277:665-667. [CrossRef][Medline]
11. Rowinsky EK, Cazenave LA, Donehower RC. Taxol: a novel investigational antimicrotubule agent. J Natl Cancer Inst 1990;82:1247-1259. [Free Full Text]
12. Rowinski EK, Eisenhauer EA, Chaudhry V, Arbuck SG, Donehower RC. Clinical toxicities encountered with paclitaxel (Taxol). Semin Oncol 1993;20:Suppl 3:1-15. [Web of Science][Medline]
13. Rowinsky EK, Donehower RC. Paclitaxel (Taxol). N Engl J Med 1995;332:1004-1014. [Erratum, N Engl J Med 1995;333:75.] [Free Full Text]
14. Axel DI, Kunert W, Göggelmann C, et al. Paclitaxel inhibits arterial smooth muscle cell proliferation and migration in vitro and in vivo using local drug delivery. Circulation 1997;96:636-645. [Free Full Text]
15. Heldman AW, Cheng L, Jenkins GM, et al. Paclitaxel stent coating inhibits neointimal hyperplasia at 4 weeks in a porcine model of coronary restenosis. Circulation 2001;103:2289-2295. [Free Full Text]
16. Herdeg C, Oberhoff M, Baumbach A, et al. Local paclitaxel delivery for prevention of restenosis: biological effects and efficacy in vivo. J Am Coll Cardiol 2000;35:1969-1976. [Free Full Text]
17. Sollott SJ, Cheng L, Pauly RR, et al. Taxol inhibits neointimal smooth muscle cell accumulation after angioplasty in the rat. J Clin Invest 1995;95:1869-1876. [Web of Science][Medline]
18. Yoon Y, Shim WH, Lee DH, et al. Usefulness of cilostazol versus ticlopidine in coronary artery stenting. Am J Cardiol 1999;84:1375-1380. [CrossRef][Web of Science][Medline]
19. Park SW, Lee CW, Kim HS, et al. Comparison of cilostazol versus ticlopidine therapy after stent implantation. Am J Cardiol 1999;84:511-514. [CrossRef][Web of Science][Medline]
20. Park SW, Lee CW, Kim HS, et al. Effects of cilostazol on angiographic restenosis after coronary stent placement. Am J Cardiol 2000;86:499-503. [CrossRef][Web of Science][Medline]
21. Kuntz RE, Safian RD, Carrozza JP, Fishman RF, Mansour M, Baim DS. The importance of acute luminal diameter in determining restenosis after coronary atherectomy or stenting. Circulation 1992;86:1827-1835. [Free Full Text]
22. Condado JA, Waksman R, Calderas C, Saucedo J, Lansky A. Two-year follow-up after intracoronary gamma radiation therapy. Cardiovasc Radiat Med 1999;1:30-35. [CrossRef][Medline]
23. Teirstein PS, Massullo V, Jani S, et al. Three-year clinical and angiographic follow-up after intracoronary radiation: results of a randomized clinical trial. Circulation 2000;101:360-365. [Free Full Text]
24. Kimura T, Abe K, Shizuta S, et al. Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation 2002;105:2986-2991. [Free Full Text]
25. Lee JH, Lee CW, Park SW, et al. Long-term follow-up after deferring angioplasty in asymptomatic patients with moderate noncritical in-stent restenosis. Clin Cardiol 2001;24:551-555. [Medline]
26. Ormiston JA, Stewart FM, Roche AH, Webber BJ, Whitlock RM, Webster MW. Late regression of the dilated site after coronary angioplasty: a 5-year quantitative angiographic study. Circulation 1997;96:468-474. [Free Full Text]
27. Hermiller JB, Fry ET, Peters TF, et al. Late coronary artery stenosis regression within the Gianturco-Roubin intracoronary stent. Am J Cardiol 1996;77:247-251. [CrossRef][Web of Science][Medline]
28. Farb A, Heller PF, Shroff S, et al. Pathological analysis of local delivery of paclitaxel via a polymer-coated stent. Circulation 2001;104:473-479. [Free Full Text]

Abstract PDF PDA Full Text PowerPoint Slide Set Editorial by Curfman, G. D. Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

This article has been cited by other articles:

• Suzuki, Y., Yeung, A. C., Ikeno, F. (2009). The Pre-Clinical Animal Model in the Translational Research of Interventional Cardiology. J Am Coll Cardiol Intv 2: 373-383 [Abstract] [Full Text]  
• Yao, E.-H., Fukuda, N., Ueno, T., Matsuda, H., Nagase, H., Matsumoto, Y., Sugiyama, H., Matsumoto, K. (2009). A pyrrole-imidazole polyamide targeting transforming growth factor-{beta}1 inhibits restenosis and preserves endothelialization in the injured artery. Cardiovasc Res 81: 797-804 [Abstract] [Full Text]  
• Zhao, D. X., Leacche, M., Balaguer, J. M., Boudoulas, K. D., Damp, J. A., Greelish, J. P., Byrne, J. G., the Writing Group on behalf of the Cardiac Surgery, (2009). Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room.. J Am Coll Cardiol 53: 232-241 [Abstract] [Full Text]  
• Chevalier, B., Di Mario, C., Neumann, F.-J., Ribichini, F., Urban, P., Popma, J. J., Fitzgerald, P. J., Cutlip, D. E., Williams, D. O., Ormiston, J., Grube, E., Whitbourn, R., Schwartz, L. B., for the ZoMaxx I Investigators, (2008). A Randomized, Controlled, Multicenter Trial to Evaluate the Safety and Efficacy of Zotarolimus- Versus Paclitaxel-Eluting Stents in De Novo Occlusive Lesions in Coronary Arteries: The ZoMaxx I Trial. J Am Coll Cardiol Intv 1: 524-532 [Abstract] [Full Text]  
• Becker, R. C., Meade, T. W., Berger, P. B., Ezekowitz, M., O'Connor, C. M., Vorchheimer, D. A., Guyatt, G. H., Mark, D. B., Harrington, R. A. (2008). The Primary and Secondary Prevention of Coronary Artery Disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest 133: 776S-814S [Abstract] [Full Text]  
• Groeneveld, P. W., Matta, M. A., Greenhut, A. P., Yang, F. (2008). Drug-Eluting Compared With Bare-Metal Coronary Stents Among Elderly Patients. J Am Coll Cardiol 51: 2017-2024 [Abstract] [Full Text]  
• Schachner, T., Steger, C., Heiss, S., Bonaros, N., Sterlacci, W., Laufer, G., Bonatti, J. (2007). Paclitaxel treatment reduces neointimal hyperplasia in cultured human saphenous veins. Eur. J. Cardiothorac. Surg. 32: 906-911 [Abstract] [Full Text]  
• Togni, M., Eber, S., Widmer, J., Billinger, M., Wenaweser, P., Cook, S., Vogel, R., Seiler, C., Eberli, F. R., Maier, W., Corti, R., Roffi, M., Luscher, T. F., Garachemani, A., Hess, O. M., Wandel, S., Meier, B., Juni, P., Windecker, S. (2007). Impact of Vessel Size on Outcome After Implantation of Sirolimus-Eluting and Paclitaxel-Eluting Stents: A Subgroup Analysis of the SIRTAX Trial. J Am Coll Cardiol 50: 1123-1131 [Abstract] [Full Text]  
• Daemen, J., Serruys, P. W. (2007). Drug-Eluting Stent Update 2007: Part I: A Survey of Current and Future Generation Drug-Eluting Stents: Meaningful Advances or More of the Same?. Circulation 116: 316-328 [Full Text]  
• Lim, Y., Kim, T.-J., Jin, Y.-R., Kim, D.-W., Kwon, J.-S., Son, J.-H., Jung, J.-C., Avery, M. A., Son, D. J., Hong, J. T., Yun, Y.-P. (2007). Epothilone B Inhibits Neointimal Formation after Rat Carotid Injury through the Regulation of Cell Cycle-Related Proteins. J. Pharmacol. Exp. Ther. 321: 648-655 [Abstract] [Full Text]  
• Hoffmann, R., Pohl, T., Koster, R., Blindt, R., Boeckstegers, P., Heitzer, T. (2007). Implantation of paclitaxel-eluting stents in saphenous vein grafts: clinical and angiographic follow-up results from a multicentre study. Heart 93: 331-334 [Abstract] [Full Text]  
• Muldowney, J. A.S. III, Stringham, J. R., Levy, S. E., Gleaves, L. A., Eren, M., Piana, R. N., Vaughan, D. E. (2007). Antiproliferative Agents Alter Vascular Plasminogen Activator Inhibitor-1 Expression: A Potential Prothrombotic Mechanism of Drug-Eluting Stents. Arterioscler. Thromb. Vasc. Bio. 27: 400-406 [Abstract] [Full Text]  
• Park, D.-W., Hong, M.-K., Mintz, G. S., Lee, C. W., Song, J.-M., Han, K.-H., Kang, D.-H., Cheong, S.-S., Song, J.-K., Kim, J.-J., Weissman, N. J., Park, S.-W., Park, S.-J. (2006). Two-Year Follow-Up of the Quantitative Angiographic and Volumetric Intravascular Ultrasound Analysis After Nonpolymeric Paclitaxel-Eluting Stent Implantation: Late "Catch-Up" Phenomenon From ASPECT Study. J Am Coll Cardiol 48: 2432-2439 [Abstract] [Full Text]  
• Klonaris, C., Katsargyris, A., Giannopoulos, A., Bastounis, E. (2006). Advances in Endovascular Treatment of Femoropopliteal Arterial Occlusive Disease. PERSPECT VASC SURG ENDOVASC THER 18: 329-341 [Abstract]  
• Nordmann, A. J., Briel, M., Bucher, H. C. (2006). Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 27: 2784-2814 [Abstract] [Full Text]  
• Lee, B. H., Nam, H. Y., Kwon, T., Kim, S. J., Kwon, G. Y., Jeon, H. J., Lim, H. J., Lee, W. K., Park, J.-s., Ko, J. Y., Kim, D. J. (2006). Paclitaxel-coated expanded polytetrafluoroethylene haemodialysis grafts inhibit neointimal hyperplasia in porcine model of graft stenosis. Nephrol Dial Transplant 21: 2432-2438 [Abstract] [Full Text]  
• Roiron, C, Sanchez, P, Bouzamondo, A, Lechat, P, Montalescot, G (2006). Drug eluting stents: an updated meta-analysis of randomised controlled trials. Heart 92: 641-649 [Abstract] [Full Text]  
• Whittaker, D. R., Fillinger, M. F. (2006). The Engineering of Endovascular Stent Technology: A Review. VASC ENDOVASCULAR SURG 40: 85-94 [Abstract]  
• Lee, C.-H., Tan, H.-C., Lim, Y.-T. (2006). Update on Drug-Eluting Stents for Prevention of Restenosis. Asian Cardiovasc. Thorac. Ann. 14: 75-82 [Abstract] [Full Text]  
• Salu, K. J., Bosmans, J. M., Huang, Y., Hendriks, M., Verhoeven, M., Levels, A., Cooper, S., De Scheerder, I. K., Vrints, C. J., Bult, H. (2006). Effects of cytochalasin D-eluting stents on intimal hyperplasia in a porcine coronary artery model. Cardiovasc Res 69: 536-544 [Abstract] [Full Text]  
• Smith, S. C. Jr, Feldman, T. E., Hirshfeld, J. W. Jr, Jacobs, A. K., Kern, M. J., King, S. B. III, Morrison, D. A., O'Neill, W. W., Schaff, H. V., Whitlow, P. L., Williams, D. O., Antman, E. M., Smith, S. C. Jr, Adams, C. D., Anderson, J. L., Faxon, D. P., Fuster, V., Halperin, J. L., Hiratzka, L. F., Hunt, S. A., Jacobs, A. K., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2006). ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). J Am Coll Cardiol 47: 216-235 [Full Text]  
• Smith, S. C. Jr, Feldman, T. E., Hirshfeld, J. W. Jr, Jacobs, A. K., Kern, M. J., King, S. B. III, Morrison, D. A., O'Neill, W. W., Schaff, H. V., Whitlow, P. L., Williams, D. O., Antman, E. M., Smith, S. C. Jr, Adams, C. D., Anderson, J. L., Faxon, D. P., Fuster, V., Halperin, J. L., Hiratzka, L. F., Hunt, S. A., Jacobs, A. K., Nishimura, R., Ornato, J. P., Page, R. L., Riegel, B. (2006). ACC/AHA/SCAI 2005 Guideline Update for Percutaneous Coronary Intervention--Summary Article: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention). Circulation 113: 156-175 [Full Text]  
• Alvarez, W. Jr, Kapur, N. K. (2005). Drug Eluting Stent Technology: A Paradigm Shift in the Treatment and Prevention of Restenosis. Journal of Pharmacy Practice 18: 461-478 [Abstract]  
• Iofina, E, Radke, P W, Skurzewski, P, Haager, P K, Blindt, R, Koch, K-C, Hanrath, P, vom Dahl, J, Hoffmann, R (2005). Superiority of sirolimus eluting stent compared with intracoronary {beta} radiation for treatment of in-stent restenosis: a matched comparison. Heart 91: 1584-1589 [Abstract] [Full Text]  
• Thiele, H., Oettel, S., Jacobs, S., Hambrecht, R., Sick, P., Gummert, J. F., Mohr, F. W., Schuler, G., Falk, V. (2005). Comparison of Bare-Metal Stenting With Minimally Invasive Bypass Surgery for Stenosis of the Left Anterior Descending Coronary Artery: A 5-Year Follow-Up. Circulation 112: 3445-3450 [Abstract] [Full Text]  
• Dawkins, K. D., Grube, E., Guagliumi, G., Banning, A. P., Zmudka, K., Colombo, A., Thuesen, L., Hauptman, K., Marco, J., Wijns, W., Popma, J. J., Koglin, J., Russell, M. E., on behalf of the TAXUS VI Investigators, (2005). Clinical Efficacy of Polymer-Based Paclitaxel-Eluting Stents in the Treatment of Complex, Long Coronary Artery Lesions From a Multicenter, Randomized Trial: Support for the Use of Drug-Eluting Stents in Contemporary Clinical Practice. Circulation 112: 3306-3313 [Abstract] [Full Text]  
• Nawarskas, J. J., Osborn, L. A. (2005). Paclitaxel-eluting stents in coronary artery disease. Am J Health Syst Pharm 62: 2241-2251 [Abstract] [Full Text]  
• Delis, K. T., Gloviczki, P. (2005). Middle Aortic Syndrome: From Presentation to Contemporary Open Surgical and Endovascular Treatment. PERSPECT VASC SURG ENDOVASC THER 17: 187-203 [Abstract]  
• Dells, K. T., Gloviczki, P. (2005). Last Word. PERSPECT VASC SURG ENDOVASC THER 17: 205-1-206  
• Windecker, S., Remondino, A., Eberli, F. R., Juni, P., Raber, L., Wenaweser, P., Togni, M., Billinger, M., Tuller, D., Seiler, C., Roffi, M., Corti, R., Sutsch, G., Maier, W., Luscher, T., Hess, O. M., Egger, M., Meier, B. (2005). Sirolimus-Eluting and Paclitaxel-Eluting Stents for Coronary Revascularization. NEJM 353: 653-662 [Abstract] [Full Text]  
• Costa, M. A., Simon, D. I. (2005). Molecular Basis of Restenosis and Drug-Eluting Stents. Circulation 111: 2257-2273 [Full Text]  
• Lansky, A. J., Costa, R. A., Mooney, M., Midei, M. G., Lui, H. K., Strickland, W., Mehran, R., Leon, M. B., Russell, M. E., Ellis, S. G., Stone, G. W., TAXUS-IV Investigators, (2005). Gender-based outcomes after paclitaxel-eluting stent implantation in patients with coronary artery disease. J Am Coll Cardiol 45: 1180-1185 [Abstract] [Full Text]  
• Delea, T. E, Jacobson, T. A, Serruys, P. W., Edelsberg, J. S, Oster, G. (2005). Cost-Effectiveness of Fluvastatin Following Successful First Percutaneous Coronary Intervention. The Annals of Pharmacotherapy 39: 610-616 [Abstract] [Full Text]  
• Bavry, A. A., Kumbhani, D. J., Helton, T. J., Bhatt, D. L. (2005). What is the risk of stent thrombosis associated with the use of paclitaxel-eluting stents for percutaneous coronary intervention?: A meta-analysis. J Am Coll Cardiol 45: 941-946 [Abstract] [Full Text]  
• Masuo, O., Terada, T., Walker, G., Tsuura, M., Nakai, K., Itakura, T. (2005). Patency of Perforating Arteries after Stent Placement? A Study Using an In Vivo Experimental Atherosclerosis-Induced Model. Am. J. Neuroradiol. 26: 543-548 [Abstract] [Full Text]  
• Levitzki, A. (2005). PDGF receptor kinase inhibitors for the treatment of restenosis. Cardiovasc Res 65: 581-586 [Abstract] [Full Text]  
• Spertus, J. A., Nerella, R., Kettlekamp, R., House, J., Marso, S., Borkon, A. M., Rumsfeld, J. S. (2005). Risk of Restenosis and Health Status Outcomes for Patients Undergoing Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graft Surgery. Circulation 111: 768-773 [Abstract] [Full Text]  
• Shin, J. H., Song, H.-Y., Choi, C. G., Yuk, S. H., Kim, J.-S., Kim, Y. M., Yoon, C. J., Kim, T.-H., Suh, J.-Y., He, X. (2005). Tissue Hyperplasia: Influence of a Paclitaxel-eluting Covered Stent--Preliminary Study in a Canine Urethral Model. Radiology 234: 438-444 [Abstract] [Full Text]  
• Langeveld, B., van Gilst, W. H., Tio, R. A., Zijlstra, F., Roks, A. J.M. (2005). Angiotensin-(1-7) Attenuates Neointimal Formation After Stent Implantation in the Rat. Hypertension 45: 138-141 [Abstract] [Full Text]  
• Murphy, G. J., Bryan, A. J., Angelini, G. D. (2004). Hybrid Coronary Revascularization in the Era of Drug-Eluting Stents. Ann. Thorac. Surg. 78: 1861-1867 [Abstract] [Full Text]  
• Choi, D., Kim, S.-K., Choi, S.-H., Ko, Y.-G., Ahn, C.-W., Jang, Y., Lim, S.-K., Lee, H.-C., Cha, B.-S. (2004). Preventative Effects of Rosiglitazone on Restenosis After Coronary Stent Implantation in Patients With Type 2 Diabetes. Diabetes Care 27: 2654-2660 [Abstract] [Full Text]  
• Grube, E., Lansky, A., Hauptmann, K. E., Di Mario, C., Di Sciascio, G., Colombo, A., Silber, S., Stumpf, J., Reifart, N., Fajadet, J., Marzocchi, A., Schofer, J., Dumas, P., Hoffmann, R., Guagliumi, G., Pitney, M., Russell, M. E. (2004). High-dose 7-hexanoyltaxol-eluting stent with polymer sleeves for coronary revascularization: One-year results from the SCORE randomized trial. J Am Coll Cardiol 44: 1368-1372 [Abstract] [Full Text]  
• Schwartz, R. S., Chronos, N. A., Virmani, R. (2004). Preclinical restenosis models and drug-eluting stents: Still important, still much to learn. J Am Coll Cardiol 44: 1373-1385 [Abstract] [Full Text]  
• Toutouzas, K., Colombo, A., Stefanadis, C. (2004). Inflammation and restenosis after percutaneous coronary interventions. Eur Heart J 25: 1679-1687 [Abstract] [Full Text]  
• Popma, J. J., Berger, P., Ohman, E. M., Harrington, R. A., Grines, C., Weitz, J. I. (2004). Antithrombotic Therapy During Percutaneous Coronary Intervention: The Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest 126: 576S-599S [Abstract] [Full Text]  
• Scheller, B., Speck, U., Abramjuk, C., Bernhardt, U., Bohm, M., Nickenig, G. (2004). Paclitaxel Balloon Coating, a Novel Method for Prevention and Therapy of Restenosis. Circulation 110: 810-814 [Abstract] [Full Text]  
• Agema, W. R.P, Monraats, P. S, Zwinderman, A. H, de Winter, R. J, Tio, R. A, Doevendans, P. A.F.M, Waltenberger, J., de Maat, M. P.M, Frants, R. R, Atsma, D. E, van der Laarse, A., van der Wall, E. E, Jukema, J.W. (2004). Current PTCA practice and clinical outcomes in The Netherlands: the real world in the pre-drug-eluting stent era. Eur Heart J 25: 1163-1170 [Abstract] [Full Text]  
• Sindermann, J. R, Verin, V., Hopewell, J. W, Rodemann, H. P., Hendry, J. H (2004). Biological aspects of radiation and drug-eluting stents for the prevention of restenosis. Cardiovasc Res 63: 22-30 [Abstract] [Full Text]  
• Colombo, A., Iakovou, I. (2004). Drug-eluting stents: the new gold standard for percutaneous coronary revascularisation. Eur Heart J 25: 895-897 [Full Text]  
• Hill, R. A., Dundar, Y., Bakhai, A., Dickson, R., Walley, T. (2004). Drug-eluting stents: an early systematic review to inform policy. Eur Heart J 25: 902-919 [Abstract] [Full Text]  
• Radke, P. W, Kobella, S., Kaiser, A., Franke, A., Schubert, D., Grube, E., Hanrath, P., Hoffmann, R. (2004). Treatment of in-stent restenosis using a paclitaxel-eluting stent: acute results and long-term follow-up of a matched-pair comparison with intracoronary {beta}-radiation therapy. Eur Heart J 25: 920-925 [Abstract] [Full Text]  
• Bettmann, M. A., Dake, M. D., Hopkins, L. N., Katzen, B. T., White, C. J., Eisenhauer, A. C., Pearce, W. H., Rosenfield, K. A., Smalling, R. W., Sos, T. A., Venbrux, A. C. (2004). Atherosclerotic Vascular Disease Conference: Writing Group VI: Revascularization. Circulation 109: 2643-2650 [Full Text]  
• Chong, P. H, Cheng, J. W. (2004). Early Experiences and Clinical Implications of Restenosis and Drug-Eluting Stents: Part 2. The Annals of Pharmacotherapy 38: 845-852 [Abstract] [Full Text]  
• Lansky, A. J., Costa, R. A., Mintz, G. S., Tsuchiya, Y., Midei, M., Cox, D. A., O'Shaughnessy, C., Applegate, R. A., Cannon, L. A., Mooney, M., Farah, A., Tannenbaum, M. A., Yakubov, S., Kereiakes, D. J., Wong, S. C., Kaplan, B., Cristea, E., Stone, G. W., Leon, M. B., Knopf, W. D., O'Neill, W. W., for the DELIVER Clinical Trial Investigators, (2004). Non-Polymer-Based Paclitaxel-Coated Coronary Stents for the Treatment of Patients With De Novo Coronary Lesions: Angiographic Follow-Up of the DELIVER Clinical Trial. Circulation 109: 1948-1954 [Abstract] [Full Text]  
• Orlic, D., Bonizzoni, E., Stankovic, G., Airoldi, F., Chieffo, A., Corvaja, N., Sangiorgi, G., Ferraro, M., Briguori, C., Montorfano, M., Carlino, M., Colombo, A. (2004). Treatment of multivessel coronary artery disease with sirolimus-eluting stent implantation: immediate and mid-term results. J Am Coll Cardiol 43: 1154-1160 [Abstract] [Full Text]  
• O'Neill, W. W., Dixon, S. R. (2004). The year in interventional cardiology. J Am Coll Cardiol 43: 875-890 [Full Text]  
• Greenberg, D., Bakhai, A., Cohen, D. J. (2004). Can we afford to eliminate restenosis?: Can we afford not to?. J Am Coll Cardiol 43: 513-518 [Abstract] [Full Text]  
• Nordmann, A. J, Hengstler, P., Leimenstoll, B. M, Harr, T., Young, J., Bucher, H. C (2004). Clinical outcomes of stents versus balloon angioplasty in non-acute coronary artery disease: A meta-analysis of randomized controlled trials. Eur Heart J 25: 69-80 [Abstract] [Full Text]  
• Bhatia, V, Bhatia, R, Dhindsa, M (2004). Drug-eluting stents: new era and new concerns. Postgrad. Med. J. 80: 13-18 [Abstract] [Full Text]  
• Moses, J. W., Leon, M. B., Popma, J. J., Fitzgerald, P. J., Holmes, D. R., O'Shaughnessy, C., Caputo, R. P., Kereiakes, D. J., Williams, D. O., Teirstein, P. S., Jaeger, J. L., Kuntz, R. E., the SIRIUS Investigators, (2003). Sirolimus-Eluting Stents versus Standard Stents in Patients with Stenosis in a Native Coronary Artery. NEJM 349: 1315-1323 [Abstract] [Full Text]  
• Mintz, G. S., Tinana, A., Hong, M.-K., Lee, C. W., Kim, J.-J., Fearnot, N. E., Park, S.-W., Park, S.-J., Weissman, N. J. (2003). Impact of Preinterventional Arterial Remodeling on Neointimal Hyperplasia After Implantation of (Non-Polymer-Encapsulated) Paclitaxel-Coated Stents: A Serial Volumetric Intravascular Ultrasound Analysis From the ASian Paclitaxel-Eluting Stent Clinical Trial (ASPECT). Circulation 108: 1295-1298 [Abstract] [Full Text]  
• Colombo, A., Drzewiecki, J., Banning, A., Grube, E., Hauptmann, K., Silber, S., Dudek, D., Fort, S., Schiele, F., Zmudka, K., Guagliumi, G., Russell, M. E. (2003). Randomized Study to Assess the Effectiveness of Slow- and Moderate-Release Polymer-Based Paclitaxel-Eluting Stents for Coronary Artery Lesions. Circulation 108: 788-794 [Abstract] [Full Text]  
• Gunn, J., Crossman, D., Grech, E. D, Cumberland, D. (2003). New developments in percutaneous coronary intervention. BMJ 327: 150-153 [Full Text]  
• Levine, G. N., Kern, M. J., Berger, P. B., Brown, D. L., Klein, L. W., Kereiakes, D. J., Sanborn, T. A., Jacobs, A. K., for the American Heart Association Diagnostic and, (2003). Management of Patients Undergoing Percutaneous Coronary Revascularization. ANN INTERN MED 139: 123-136 [Abstract] [Full Text]  
• Malik, I. (2003). JournalScan. Heart 89: 815-816 [Full Text]  
• Lemos, P. A., Serruys, P. W., Sousa, J. E. (2003). Drug-Eluting Stents: Cost Versus Clinical Benefit. Circulation 107: 3003-3007 [Full Text]  
• Curfman, G. D., Morrissey, S., Drazen, J. M. (2003). Notice of Duplicate Publication. NEJM 348: 2254-2254 [Full Text]  
• (2003). Paclitaxel-Eluting Stent Prevents Restenosis. Journal Watch Cardiology 2003: 1-1 [Full Text]